Aadi Bioscience Files Definitive Proxy Statement

TL;DR

Aadi Bioscience filed its proxy statement, standard procedure, no major news here.

AI Summary

Aadi Bioscience, Inc. filed a Definitive Proxy Statement (DEFA14A) on December 30, 2024. This filing is soliciting material under Rule 14a-12, indicating it's not a preliminary proxy statement. The company, previously known as Aerpio Pharmaceuticals, Inc. and Zeta Acquisition Corp II, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing is a standard regulatory document that provides information to shareholders regarding company matters, though it does not contain specific proposals or financial details in this excerpt.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not contain new financial information or strategic decisions that would immediately impact risk.

Key Players & Entities

• Aadi Bioscience, Inc. (company) — Registrant
• Aerpio Pharmaceuticals, Inc. (company) — Former Company Name
• ZETA ACQUISITION CORP II (company) — Former Company Name
• 20241230 (date) — Filing Date

FAQ

Key Financial Figures

• $100 m — astructure to Kaken Pharmaceuticals for $100 million, allowing for the continued distr
• $63 million — tween cash on hand that was reported at $63 million at the end of 2023, $100 million from t
• $100 million — rted at $63 million at the end of 2023, $100 million from the sale of FYARRO, and $100 milli
• $25 million — YARRO, including cumulative revenues of $25 million reported over the prior four quarters a
• $58 million — r four quarters and cumulative sales of $58 million since launch. Kaken is an R&D-driven
• $44 million — will pay aggregate up-front payments of $44 million for in-licensing these three ADC progra
• $265 m — ative development milestone payments of $265 million, cumulative commercial milestone
• $540 m — lative commercial milestone payments of $540 million, and single-digit royalties on an
• $2.40 — y is selling common stock at a price of $2.40 per share, representing a premium of ap
• $1.8 billion — cquired earlier this year by Genmab for $1.8 billion in May of 2024. Prior to Profound, Ba

Filing Documents

• d46843ddefa14a.htm (DEFA14A) — 58KB
• 0001193125-24-286907.txt ( ) — 59KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 AADI BIOSCIENCE, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Aadi Bioscience, Inc. (Aadi Bioscience, Inc. Investor Call) December 20, 2024 Corporate Speakers: Audrey Gross; Aadi Bioscience, Inc; Head of Corporate Communications Dave Lennon; Aadi Bioscience, Inc; President and Chief Executive Officer Scott Giacobello; Aadi Bioscience, Inc; Chief Financial Officer Participants: Tara Bancroft; TD Cowen; Analyst Liang Cheng; Jefferies; Analyst PRESENTATION Operator: Good day and welcome to the Aadi update call. At this time, all participants are in a listen-only mode. After the speakers presentation, there will be a question-and-answer session. Instructions will be given at that time. As a reminder, this call may be recorded. I would now like to turn the call over to Audrey Gross, Head of Corporate Communications for Aadi Bioscience. Ms. Gross, please go ahead. Audrey Gross: Thank you. Good morning and welcome to the Aadi Bioscience conference call. We will be presenting slides as part of a live webcast of this call. Such slides will be posted on the investor news page of the Aadi Bioscience website at Aadibio.com following the conference call. A reminder that factors, including those set forth in the risk factors section of our annual and quarterly filing with the Securities and Exchange Commission, which can be found at www.sec.gov or on our website at Aadibio.com. In addition, any forward-looking statements made on the call represent our views only as of today, December 20, 2024, and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. On the call today is Dr. Dave Lennon, our President and CEO, and Scott Giacobello, our CFO. Today we will provide an overview of the strategic updates announced yesterday before opening the call for questions. Ill now turn the call over to Dave. Dave? Dave Lennon: Great, thank you, Audrey. Good morning, everyone, and thank you for joining us today. Were extremely excited about the proposed transactions weve laid out in our press release that youve probably seen, and Im eager to dive into the details with you today. So Id like to start on slide five. Ill remind you that Aadis long-term vision has always been to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. These transactions, while transformative for us as a company, are rooted in Aadis legacy as a precision oncology biotech. The unique combination of these transactions will position us to further advance our mission for patients and create significant long-term value for shareholders. First, we have entered an agreement to sell FYARRO and the associated infrastructure to Kaken Pharmaceuticals for $100 million, allowing for the continued distribution and growth of FYARRO in PEComa and potentially beyond with an innovative R&D-focused pharmaceutical company and with Kakens stated desire to grow its commercial footprint in the U.S. In our second transaction, we have entered an agreement to license three preclinical antibody drug conjugates, or ADCs, from WuXi Biologics, a leading global CRDMO that leverages an advanced linker-payload technology from Hangzhou DAC, an ADC platform leader founded over a dozen years ago. Acquisition to the rights of these portfolio resets Aadis potential with three high-potential assets focused in precision oncology, but now in the exciting field of ADCs. In our third transaction, weve announced a PIPE Financing of $100 million, ensuring sufficient capital and allowing our ability to enter the clinic and deliver key clinical updates on all three of these assets. In total, between cash on hand that was reported at $63 million at the end of 2023, $100 million from the sale of FYARRO, and $100 million from the PIPE Financing, we believe Aadi starts with a capital position giving us cash runway into the latter half of 2028. Now lets take a closer look at each transaction. On slide six, as mentioned, Kaken Pharmaceutical and Aadi have entered

View Full Filing

View this DEFA14A filing on SEC EDGAR